Therefore, our study unveils a dysregulation of circulating ILCs in PCa, with a notable increase in ILC2 populations at the expense of ILC1s, identifying these two ILC subsets as potential therapeutic targets for the treatment of PCa. The gene discussed is CCL27; the disease is posterior cortical atrophy.